Arestat™ stabilisation technologies are inspired by Arecor’s unique insights into the ways in which stability of various molecules, such as proteins or other biologics, can be controlled. There are a number of degradation pathways that lead to the undesirable loss of activity, loss of native structure or aggregation.

Arestat™ is a set of proprietary formulation ‘tools’ to address the principal pathways of degradation that lead to the loss of structural integrity and biological activity. The technology was designed as an extension to the conventional approaches to formulation of biologics. Traditionally, the stability of biologics is controlled by optimisation of basic formulation parameters, such as pH, ionic strength, and nature of buffer or surfactant selection. Arestat™ brings many new dimensions to the conventional formulation design space, and allows formulation of biologics with superior stability. The technology is based on using specific combinations of excipients and conditions in order to prevent the key degradation processes.

Arestat™ comprises three different aspects of stabilisation. All three utilise FDA and EMEA approved buffers and excipients in an unconventional manner to achieve the desired stability.

• Arestat-T™ is concerned with the stabilisation of biologics during storage at refrigerated, ambient or elevated temperatures.
• Arestat-C™ proteins, particularly antibodies, at high concentrations.
• Arestat-R™, is concerned with the stabilisation of biologics exposed to ionising radiation (e.g. gamma radiation).

Arestat-T™, Arestat-C™ and Arestat-R™ can be applied as stand-alone solutions or in combination to improve significantly the stability of recombinant proteins, vaccines and other molecules.